Affiliation:
1. Biobizkaia Health Research Institute and University of The Basque Country‐UPV/EHU Bizkaia Basque Country Spain
2. Biobizkaia Health Research Institute Bizkaia Basque Country Spain
3. University of The Basque Country‐UPV/EHU Bizkaia Basque Country Spain
4. Hospital Universitario Cruces, Bizkaia, Basque Country, UNIR Health Sciences School and Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain
5. Hospital Universitario Cruces, Bizkaia, Basque Country, Hospital Regional Universitario de Málaga and Universidad de Málaga Málaga Spain
6. Bordeaux Hospital University Bordeaux France
Abstract
ObjectiveThe objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation.MethodsWe conducted an observational study of routine clinical care data from the Lupus‐Cruces‐Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: <6, 6 to 12, and >12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed.ResultsTwo hundred thirty‐three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS‐adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04–623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27–21.97, P = 0.022) and moderate‐severe SLE activity (adjusted OR 4.07, 95% CI 1.11–14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer‐term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone.ConclusionThis study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission.image
Funder
Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
Consejería de Transformación Económica, Industria, Conocimiento y Universidades
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献